LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LH is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has bullish momentum and supportive analyst targets, but the RSI is extremely overbought and hedge funds are selling aggressively. Since the user is impatient and does not want to wait for an ideal entry, the current setup is still not attractive enough to recommend an outright buy at this price.
Trend is bullish in the short term: MACD histogram is positive and expanding, and moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price is trading above the pivot and near resistance, with R1 at 283.419 already exceeded and R2 at 291.549 overhead. However, RSI_6 at 86.99 signals the stock is very overbought, which makes the current level less favorable for a new entry despite the uptrend.
Analyst sentiment is constructive: Baird raised its price target to $334 and keeps an Outperform rating, while Evercore ISI raised its target to $300 and also keeps an Outperform rating. News shows an upcoming Q2 2026 earnings release and webcast, which can act as an event-driven catalyst. The technical trend is still upward, and call-heavy daily option volume suggests traders are positioning for continued upside.
RSI is deeply overbought, which makes the stock vulnerable to near-term cooling after the recent run. Hedge funds are selling and the selling pace increased sharply over the last quarter, which is a meaningful negative. The stock trend model suggests only modest near-term gains and even weakness over the next month. There is no recent insider buying, and no congress trading data to support a bullish political flow.
No latest-quarter financial snapshot was provided, so I cannot assess the actual Q2 2026 results yet. The only financial event available is the upcoming Q2 2026 earnings release before the market open on 2026-07-30, which means the next confirmed fundamental catalyst has not occurred yet.
Recent analyst trend is positive: Evercore ISI lifted its target to $300 from $280 and maintained Outperform, and Baird raised its target to $334 from $332 and kept Outperform. Wall Street pros are clearly constructive on Labcorp's medium-term outlook. The main con is that despite the optimistic ratings, the current price is already extended and hedge fund flow is negative, so analysts support the name but not necessarily this entry point.
